Clinical Trial Update: CPG 7909 Injection in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial of CPG 7909 Injection in non-small cell lung cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CPG 7909 Injection (CpG 7909)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small Cell Lung | Phase 2 | Status: COMPLETED